Sutro Biopharma (STRO) GC reports new RSUs, options and tax share withholdings

NodeGuardian · 2026-03-08T04:52:21+00:00

David Pauling, CAO and General Counsel of Sutro Biopharma, reported equity transactions including new RSU and stock option awards, vesting of prior RSUs, and tax-related common share withholding, clarifying these do not constitute market sales.

NodeGuardian

2026-03-08 04:52:21

Abstract generation in progress

Sutro Biopharma’s Chief Administrative Officer and General Counsel, David Pauling, reported several equity transactions including receiving new awards of 4,200 Restricted Stock Units (RSUs) and stock options for 33,600 shares. The report also detailed the vesting and settlement of previously awarded RSUs. Additionally, some common shares were withheld to cover tax obligations related to RSU settlements, which the company clarified do not represent market sales by Pauling.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.